UBS AM
VTVT icon

UBS AM’s vTv Therapeutics VTVT Stock Holding History

UBS AM’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,944
Closed -$559K – 2671
2016
Q3 		$559K Sell
1,944
-2,040
-51% -$491K ﹤0.01% 1919
2016
Q2 		$924K Sell
3,984
-2,203
-36% -$507K ﹤0.01% 1687
2016
Q1 		$1.28M Sell
6,187
-2,086
-25% -$519K ﹤0.01% 1541
2015
Q4 		$2.25M Sell
8,273
-649
-7% -$182K ﹤0.01% 1384
2015
Q3 		$2.33M Buy
+8,922
New +$3.11M ﹤0.01% 1353

Other funds holding VTVT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

UBS AM's VTVT Position: Q4 2016 in Review

UBS AM sold out of vTv Therapeutics (VTVT) in Q4 2016, closing a stake of 1,944 shares — an estimated $559K sold.

UBS AM first reported a position in VTVT in Q3 2015 and held it in 5 quarters. The position peaked at $2.33M in Q3 2015. 44 funds tracked by Wall St. Rank hold VTVT as of Q4 2016.

  • UBS AM reported no remaining vTv Therapeutics position as of Q4 2016 after selling out during the quarter.
  • UBS AM sold 1,944 vTv Therapeutics shares in Q4 2016, an estimated $559K.
  • UBS AM first reported a position in vTv Therapeutics in Q3 2015 and held it in 5 quarters.
  • UBS AM's vTv Therapeutics position peaked at $2.33M in Q3 2015.
  • 44 funds tracked by Wall St. Rank held vTv Therapeutics as of Q4 2016.

Based on UBS AM's 13F filing for Q4 2016, filed 14 Feb 2017.